SCHEMBL5625992

SCHEMBL5625992

CCOC(=O)N(Cc1cc(C(F)(F)F)cc(C(F)(F)F)c1)Cc1cc2ccccc2nc1N(CC)CC1CCC1

nearest known ligand 0.40

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
CETP P11597 12/20 0.40
GPBAR1 Q8TDU6 3/20 0.38
DHFR P00374 1/20 0.37
BACE1 P56817 1/20 0.35
TACR1 P25103 2/20 0.35
TRPM8 Q7Z2W7 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5625126 0.98 CETP (0.39) CETPGPBAR1DHFRBACE1TACR1
SCHEMBL19440358 0.96 CETP (0.38) CETPGPBAR1DHFRBACE1TACR1
SCHEMBL16743066 0.94 CETP (0.38) CETPGPBAR1DHFRBACE1TACR1
SCHEMBL5624201 0.93 CETP (0.39) CETPGPBAR1BACE1TACR1TRPM8
SCHEMBL5623604 0.93 CETP (0.47) CETP
SCHEMBL5624969 0.91 CETP (0.47) CETP
SCHEMBL19188629 0.91 GPBAR1 (0.47) CETPGPBAR1BACE1TACR1TRPM8
SCHEMBL16743071 0.90 CETP (0.43) CETP
SCHEMBL5623759 0.90 CETP (0.48) CETP
SCHEMBL16743068 0.89 CETP (0.38) CETPGPBAR1DHFRBACE1TRPM8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9782407-B2 Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors DR. REDDY'S LABORATORIES LTD. (IN) 2017-10-10 US disclosed
US-8604055-B2 Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors DR. REDDY'S LABORATORIES LTD. (IN) 2013-12-10 US disclosed
US-20070015758-A1 Novel benzylamine derivatives and their utility as cholesterol ester-transfer protein inhibitors DR. REDDY'S LABORATORIES LTD. (IN) 2007-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070015758-A1 Novel benzylamine derivatives and their utility as cholesterol ester-transfer protein inhibitors CETP, NPC1, DBI CETP 1/4885GPBAR1 258/4885DHFR 4323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.